Old West Investment Management LLC trimmed its position in Theravance Biopharma Inc (NASDAQ:TBPH) by 4.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 109,320 shares of the biopharmaceutical company
Housing starts point to continued strength in residential housing. Supporting the growth is an increasing homeownership rate as younger buyers enter the market and wages continue to rise.
Masonite International profits from a hot housing market via new construction and renovations. Through acquisitions and economies of scale, DOOR has seen improved net profit margins and efficiency returns....More>>>
It’s been a rough year or so for gun makers. Absent the fear among gun owners that the federal government will in some way restrict gun purchases and ownership, gun sales have tanked.
In an exclusive report, Reuters cites people familiar with the matter who say that iconic gun maker Remington Arms is searching for financing to allow the firm to file for bankruptcy protection. Remington....More>>>
Very few hedge fund managers start with $2 billion from investor George Soros. One who did, Scott Bessent, has already given much of it back.
As Bessent has gathered capital since his firm’s 2016 launch, he has returned Soros’s money as part of an arrangement between the two, according to a person familiar with Soros’s family office who requested anonymity. Soros had....More>>>
BB&T Securities LLC raised its holdings in Aon PLC (NYSE:AON) by 6.2% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 23,068 shares of the financial services provider’s stock after purchasing an additional 1,352 shares during the period. BB&
US Bancorp DE raised its stake in shares of Aon (NYSE:AON) by 3.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,448 shares of the financial services provider’s stock after acquiring an additional 1,178 shares during the quart
With three product candidates in the pipeline, at a very early stage, Scholar Rock will need a long time to see the FDA approving them. That said, the company has many patents, a licence with Janssen Biotech, and a fantastic team of professionals. While the risk may be too high for the individua